A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

Blood
Oreofe OdejideDavid M Weinstock

Abstract

The genetics of angioimmunoblastic T-cell lymphoma (AITL) are very poorly understood. We defined the mutational landscape of AITL across 219 genes in 85 cases from the United States and Europe. We identified ≥2 mutations in 34 genes, nearly all of which were not previously implicated in AITL. These included loss-of-function mutations in TP53 (n = 4), ETV6 (n = 3), CCND3 (n = 2), and EP300 (n = 5), as well as gain-of-function mutations in JAK2 (n = 2) and STAT3 (n = 4). TET2 was mutated in 65 (76%) AITLs, including 43 that harbored 2 or 3 TET2 mutations. DNMT3A mutations occurred in 28 (33%) AITLs; 100% of these also harbored TET2 mutations (P < .0001). Seventeen AITLs harbored IDH2 R172 substitutions, including 15 with TET2 mutations. In summary, AITL is characterized by high frequencies of overlapping mutations in epigenetic modifiers and targetable mutations in a subset of cases.

References

Mar 8, 2008·Science·Georg LenzLouis M Staudt
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie VoseUNKNOWN International T-Cell Lymphoma Project
Oct 5, 2010·Cancer Research·K-John J CheungDouglas E Horsman
Mar 11, 2011·Nature·Laura PasqualucciRiccardo Dalla-Favera
Jul 29, 2011·Nature·Ryan D MorinMarco A Marra
Nov 17, 2011·Blood·Veronica BalattiCarlo M Croce
Jan 6, 2012·The New England Journal of Medicine·Lucile CouronnéOlivier A Bernard
May 18, 2012·The New England Journal of Medicine·Hanna L M KoskelaSatu Mustjoki
Jan 11, 2013·Nature Reviews. Cancer·Mark WadeGeoffrey M Wahl
Jul 17, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pier Paolo PiccalugaStefano A Pileri
Feb 15, 2014·World Journal of Clinical Cases·Federico GobbiZeno Bisoffi

❮ Previous
Next ❯

Citations

Feb 1, 2014·International Journal of Hematology·Pier Paolo PiccalugaStefano A Pileri
Feb 11, 2014·International Journal of Hematology·Andrew M Intlekofer, Anas Younes
Mar 29, 2014·Nature Genetics·Jan Cools
Aug 19, 2014·Trends in Genetics : TIG·Yun Huang, Anjana Rao
Jan 15, 2015·Nature Communications·Can KüçükWing C Chan
Jan 21, 2016·Expert Review of Hematology·Hsin-An Hou, Hwei-Fang Tien
Nov 18, 2015·The American Journal of Surgical Pathology·Sarah L OndrejkaEric D Hsi
Jun 25, 2015·Journal of Clinical and Experimental Hematopathology : JCEH·Thien Phu TruongShigeru Chiba
Mar 29, 2016·Trends in Cancer·Maria GuillamotIannis Aifantis
Jan 15, 2016·Journal of Clinical and Experimental Hematopathology : JCEH·Kazuya ShimodaAkira Kitanaka
Sep 27, 2015·American Journal of Hematology·Ryan A Wilcox
Mar 5, 2016·Surgical Pathology Clinics·Sarah L Ondrejka, Eric D Hsi
Nov 11, 2015·Molecules and Cells·Jae-A HanMyunggon Ko
Mar 5, 2016·International Journal of Hematology·Hamza CelikGrant A Challen
Nov 26, 2015·Current Opinion in Cell Biology·Myunggon KoAnjana Rao
Nov 27, 2015·Nature Communications·Jungeun AnAnjana Rao
Jul 16, 2015·Cancer Science·Noriaki YoshidaMasao Seto
Jul 22, 2014·Cancer Science·Hideaki Nakajima, Hiroyoshi Kunimoto
May 13, 2014·British Journal of Haematology·Matthew J AhearneSimon D Wagner
Dec 17, 2014·Immunological Reviews·Myunggon KoAnjana Rao
Dec 17, 2014·Immunological Reviews·Giorgio InghiramiUNKNOWN AIRC 5xMille consortium ‘Genetics-driven targeted management of lymphoid malignancies’
Jun 11, 2015·Hematological Oncology·Greg Hapgood, Kerry J Savage
Jun 23, 2015·IUBMB Life·Feng PanMingjiang Xu
Apr 22, 2015·Cancer Genetics·Aparna Vasanthakumar, Lucy A Godley
Jul 5, 2015·Current Oncology Reports·Jennifer K LueOwen A O'Connor
Jun 25, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y ShiX Lu
Jan 13, 2015·Biochimica Et Biophysica Acta·Leonie I KroezeJoop H Jansen
Apr 16, 2015·Cancer Cell·Ramona CrescenzoUNKNOWN European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymp
Mar 1, 2014·Blood·Sonali M Smith
Jan 17, 2015·Nature Immunology·Hideki UenoCarola G Vinuesa
Nov 27, 2014·The New England Journal of Medicine·Siddhartha JaiswalBenjamin L Ebert
Jun 29, 2016·Cytokine·Jan PencikLukas Kenner
Sep 28, 2016·Intractable & Rare Diseases Research·Xianping LuXinhao Wang
Jun 24, 2016·Blood·Valeria SpinaDavide Rossi
Oct 16, 2016·International Journal of Clinical Oncology·Helen Ma, Maher Abdul-Hay
Oct 25, 2016·Experimental Hematology·Keisuke Kataoka, Seishi Ogawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.